ISRG vs RBOT

Intuitive Surgical (ISRG) continues to demonstrate strong operational performance, evidenced by its Q4 2025 revenue growth of 18.8% YoY and robust EPS beat. It maintains its undisputed leadership in robotic-assisted surgery, supported by a growing installed base of 11,423 da Vinci systems and impressive Ion system adoption. The company's formidable moat, built on IP, high switching costs, and exte...

Score Change Explanation: The score has significantly declined from 4.2/10 (42/100) to 2.2/10 (22/100). This substantial decrease is primarily driven by the material negative development of the company's delisting from the NYSE to the OTC market in early March 2026. This move severely impacts market visibility, liquidity, and investor confidence, which are critical for a company pursuing 10x growt...